Skip to main content

REVIEW article

Front. Cell Dev. Biol.
Sec. Stem Cell Research
Volume 12 - 2024 | doi: 10.3389/fcell.2024.1410102
This article is part of the Research Topic Advances in Translational and Applied Stem Cell Biology View all 5 articles

Prostate cancer stem cells and its targeted therapies

Provisionally accepted
Huilan Su Huilan Su 1Liqun Huang Liqun Huang 2Dean G. Tang Dean G. Tang 3Jianjun Zhou Jianjun Zhou 1*Guosheng Yang Guosheng Yang 2*
  • 1 Other, Shanghai, China
  • 2 Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
  • 3 Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo, New York, United States

The final, formatted version of the article will be published soon.

    Prostate cancer (PCa) is the most common malignancy amongst men worldwide.Through androgen receptor signaling inhibitors (ARSIs) treatment, patients eventually succumb to castration-resistant prostate cancer (CRPC). For this, the prostate cancer stem cells (PCSC) as the minor population of tumor cells, which possess the capability of tumour promoting relapse, ARSI resistance, and disease progression, are gaining attention. Therefore, the specific therapy targeting PCSC has been a striking momentum. This study reviewed the identification and characterization of PCSC, PCSC-based putative biomarkers, and summarized their mechanisms of action. We further discussed clinical trials of novel therapeutic interventions focused on PCSC-related pathways, PCSC microenvironment, cutting-edge miRNA therapy, and immunotherapy approaches from mechanistic standpoint. This review hopes to provide an updated insights for PCSC plasticity, the identification of new PCSC biomarkers, and optimized treatments for advanced PCa patients.

    Keywords: prostate cancer, prostate cancer stem cells, basal progenitor cells, Luminal progenitor cells, targeted therapy

    Received: 31 Mar 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 Su, Huang, Tang, Zhou and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jianjun Zhou, Other, Shanghai, China
    Guosheng Yang, Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.